Research and Markets: Global Dermatology Drug Pipeline Capsule - 2012

Research and Markets: Global Dermatology Drug Pipeline Capsule - 2012

<0> Research and MarketsLaura Wood, Senior Manager.U.S. Fax: 646-607-1907Fax (outside U.S.): +353-1-481-1716Sector: </0>

() has announced the addition of the report to their offering.

Fore Pharma's latest report Global Dermatology Drug Pipeline Capsule - 2012' provides up-to-date information on key research and development activities in the global dermatology drug market. It covers active pipeline molecules under development in various stages of clinical trials, preclinical research, and drug discovery for Acne, Alopecia, Atopic Dermatitis, Malignant Melanoma, Psoriasis, and Rosacea.

This report helps executives track their competitor's pipeline molecules. The information presented in this report can be used for identifying partners, evaluating business opportunities, formulating business development strategies, and executing in-licensing and out-licensing deals.

The report provides information on pipeline molecules by company, mechanism of action, stage (phase 3 clinical trials, phase 2 clinical trials, phase 1 clinical trials, preclinical research, and drug discovery), and geography (North America, Europe, and Asia).

- Dermatology Drug Pipeline Insights

- Acne Drug Pipeline Insights

- Alopecia Drug Pipeline Insights

- Atopic Dermatitis Drug Pipeline Insights

- Malignant Melanoma Drug Pipeline Insights

- Psoriasis Drug Pipeline Insights

- Rosacea Drug Pipeline Insights

Suggested Articles

An oncologist leader RBC Capital Markets interviewed expressed comfort that Trodelvy will succeed in earlier-line TNBC and in HR-positive disease.

Gilead Sciences is the latest drugmaker to settle Justice Department claims that its charity contributions were actually kickbacks.

J&J figures its partner Genmab owes a share of Darzalex Faspro royalties to Halozyme for its subcutaneous delivery tech. Genmab doesn't agree.